BR112022022015A2 - Composto, composição ou combinação farmacêutica e usos da composição farmacêutica ou combinação - Google Patents
Composto, composição ou combinação farmacêutica e usos da composição farmacêutica ou combinaçãoInfo
- Publication number
- BR112022022015A2 BR112022022015A2 BR112022022015A BR112022022015A BR112022022015A2 BR 112022022015 A2 BR112022022015 A2 BR 112022022015A2 BR 112022022015 A BR112022022015 A BR 112022022015A BR 112022022015 A BR112022022015 A BR 112022022015A BR 112022022015 A2 BR112022022015 A2 BR 112022022015A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- composition
- pharmaceutical
- compound
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063018427P | 2020-04-30 | 2020-04-30 | |
| PCT/CN2021/090718 WO2021219040A1 (en) | 2020-04-30 | 2021-04-28 | Histone deacetylase inhibitors for immunomodulation in tumor microenvironment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022015A2 true BR112022022015A2 (pt) | 2022-12-13 |
Family
ID=78373345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022015A BR112022022015A2 (pt) | 2020-04-30 | 2021-04-28 | Composto, composição ou combinação farmacêutica e usos da composição farmacêutica ou combinação |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11672788B2 (https=) |
| EP (1) | EP4142733B1 (https=) |
| JP (1) | JP7748392B2 (https=) |
| KR (1) | KR20230005939A (https=) |
| CN (1) | CN116033904A (https=) |
| AU (1) | AU2021265994B2 (https=) |
| BR (1) | BR112022022015A2 (https=) |
| ES (1) | ES3051512T3 (https=) |
| HR (1) | HRP20251279T1 (https=) |
| IL (1) | IL297687A (https=) |
| MX (1) | MX2022013634A (https=) |
| NZ (1) | NZ794355A (https=) |
| PL (1) | PL4142733T3 (https=) |
| TW (1) | TWI849310B (https=) |
| WO (1) | WO2021219040A1 (https=) |
| ZA (1) | ZA202212650B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115322171B (zh) * | 2022-08-30 | 2023-03-17 | 深圳微芯生物科技股份有限公司 | 一种trka(g667c)和flt3靶点抑制剂及其与西达本胺的组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| EP1738752A1 (en) * | 2002-12-27 | 2007-01-03 | Schering Aktiengesellschaft | Pharmaceutical combinations comprising cis-retine acid |
| DK1696898T3 (en) | 2003-12-02 | 2016-02-22 | Univ Ohio State Res Found | ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS |
| CA2702536A1 (en) * | 2007-10-10 | 2009-04-16 | Orchid Research Laboratories Limited | Novel histone deacetylase inhibitors |
| CN103880736B (zh) * | 2014-04-04 | 2017-05-17 | 深圳微芯生物科技有限责任公司 | 一种e构型苯甲酰胺类化合物及其药用制剂与应用 |
| CN106916101B (zh) | 2017-02-15 | 2020-05-01 | 聚缘（上海）生物科技有限公司 | Nampt/hdac双靶点抑制剂及其制备方法 |
| IL264068B2 (en) * | 2018-01-05 | 2023-07-01 | Great Novel Therapeutics Biotech & Medicals Corp | Aggregate and pharmaceutical preparation containing an hdac inhibitor and an nsaid aggregate together with an immune checkpoint inhibitor for use in a method for removing immunosuppression in the microenvironment of a tumor or stimulating an immune system against cancer cells |
-
2021
- 2021-04-28 HR HRP20251279TT patent/HRP20251279T1/hr unknown
- 2021-04-28 TW TW110115446A patent/TWI849310B/zh active
- 2021-04-28 BR BR112022022015A patent/BR112022022015A2/pt not_active Application Discontinuation
- 2021-04-28 PL PL21796395.8T patent/PL4142733T3/pl unknown
- 2021-04-28 MX MX2022013634A patent/MX2022013634A/es unknown
- 2021-04-28 ES ES21796395T patent/ES3051512T3/es active Active
- 2021-04-28 WO PCT/CN2021/090718 patent/WO2021219040A1/en not_active Ceased
- 2021-04-28 JP JP2022565835A patent/JP7748392B2/ja active Active
- 2021-04-28 AU AU2021265994A patent/AU2021265994B2/en active Active
- 2021-04-28 US US17/243,378 patent/US11672788B2/en active Active
- 2021-04-28 KR KR1020227042007A patent/KR20230005939A/ko active Pending
- 2021-04-28 NZ NZ794355A patent/NZ794355A/en unknown
- 2021-04-28 EP EP21796395.8A patent/EP4142733B1/en active Active
- 2021-04-28 IL IL297687A patent/IL297687A/en unknown
- 2021-04-28 CN CN202180031935.4A patent/CN116033904A/zh active Pending
-
2022
- 2022-11-21 ZA ZA2022/12650A patent/ZA202212650B/en unknown
-
2023
- 2023-05-01 US US18/310,387 patent/US12213971B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ794355A (en) | 2026-02-27 |
| AU2021265994A1 (en) | 2022-12-15 |
| KR20230005939A (ko) | 2023-01-10 |
| EP4142733A1 (en) | 2023-03-08 |
| US20230263790A1 (en) | 2023-08-24 |
| ZA202212650B (en) | 2024-04-24 |
| EP4142733B1 (en) | 2025-10-01 |
| TWI849310B (zh) | 2024-07-21 |
| HRP20251279T1 (hr) | 2025-12-05 |
| ES3051512T3 (en) | 2025-12-29 |
| MX2022013634A (es) | 2022-11-16 |
| US11672788B2 (en) | 2023-06-13 |
| IL297687A (en) | 2022-12-01 |
| US20210379032A1 (en) | 2021-12-09 |
| TW202200557A (zh) | 2022-01-01 |
| CN116033904A (zh) | 2023-04-28 |
| JP7748392B2 (ja) | 2025-10-02 |
| AU2021265994B2 (en) | 2024-02-29 |
| US12213971B2 (en) | 2025-02-04 |
| CA3176748A1 (en) | 2021-11-04 |
| WO2021219040A1 (en) | 2021-11-04 |
| PL4142733T3 (pl) | 2026-01-19 |
| EP4142733C0 (en) | 2025-10-01 |
| JP2023524230A (ja) | 2023-06-09 |
| EP4142733A4 (en) | 2023-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| CU20220027A7 (es) | COMPUESTOS QUÍMICOS DERIVADOS SUSTITUIDOS DEL ÁCIDO PROPANOICO ÚTILES EN LA INHIBICIÓN DE INTEGRINA A4ß7 HUMANA Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN | |
| TR199902622T2 (xx) | Enflamatuvar hastal�klar�n tedavisinde faydal� ikameli imidazoller. | |
| EA200401199A1 (ru) | Ингибиторы гистондеацетилазы | |
| WO2021226074A3 (en) | Detecting melanoma | |
| EA200401197A1 (ru) | Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы | |
| MX2021005463A (es) | Derivados de espiro-sulfonamida como inhibidores de la proteina de leucemia de celula mieloide 1 (mcl-1). | |
| CY1119405T1 (el) | Ενωση για την αναστολη ενζυμων | |
| CY1113470T1 (el) | Παραγωγα ν-(αμινο-ετεροαρυλ)-1η-ινδολο-2-καρβοξαμιδιων ως ανταγωνιστες υποδοχεων τυπου trpv1 ή vr1 | |
| BRPI0409879A (pt) | composições e métodos para imunoterapia especìfica wt1 | |
| UA108240C2 (uk) | Похідні гексафторізопропілкарбамату, їх одержання і їх терапевтичне застосування | |
| CR20220561A (es) | Nuevos inhibidores macrocíclicos de la quinasa de lrrk2 | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| BR112022018995A2 (pt) | Composições para higiene pessoal | |
| ATE449069T1 (de) | Aminopropanolderivate | |
| BR112022018929A2 (pt) | Inibidores da ciclofilina e seus usos | |
| DE60219005D1 (de) | Feste pharmazeutische formulierung enthaltend modafinil | |
| MX2023014154A (es) | Anticuerpos anti-ccr8. | |
| EP4233865A3 (en) | Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers | |
| BR0315820A (pt) | Inibidores de integrase de hiv, composições farmacêuticas e métodos para a sua utilização | |
| BR112022022015A2 (pt) | Composto, composição ou combinação farmacêutica e usos da composição farmacêutica ou combinação | |
| Licht et al. | Transcriptional heterogeneity and the microbiome of cutaneous T-cell lymphoma | |
| MX2024012565A (es) | Composiciones farmaceuticas de mosunetuzumab y metodos de uso | |
| MX2025013782A (es) | Compuesto de sulfonamida, metodo de preparacion del mismo, y uso farmaceutico del mismo | |
| ECSP077240A (es) | Variantes mejoradas de la aprotinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |